Novartis Halts Lu-NeoB Development After Early Clinical Data Fall Short
Novartis has discontinued the development of Lu-NeoB, an experimental cancer therapy designed to seek out tumor cells and deliver targeted radiation.
Search results for "Novartis"
Novartis to Buy UK Biotech Myricx for Up to $1.5 Billion, Boosting ADC Portfolio
Novartis is significantly expanding its oncology portfolio after securing an antibody-drug conjugate technology designed to deliver potent anticancer...
SK Plasma Launches High-Dose Revolpag 75 mg to Simplify Thrombocytopenia Regimens and Cut Costs
SK Plasma announced on Sept. 1 that it has begun distributing Revolpag Tablets 75 mg in South Korea, expanding its...
Global Asset Managers Expand Holdings in South Korean Pharma and Biotech
Major institutional asset managers are steadily increasing their equity stakes in South Korean pharmaceutical and...
Will a 'Second Gleevec' Emerge? The Race Heats Up for Rare Gastrointestinal Cancer Breakthroughs
A rare cancer can form in the wall of the stomach or intestines: gastrointestinal stromal tumor, or GIST.
Will Curocell’s First CAR-T Blood Cancer Drug Secure Approval Next Month?
A final decision on the approval of RIMQARTO (anbalcabtagene autoleucel), a chimeric antigen receptor T-cell (CAR-T)...
1